The Nodule Problem Pulmonary nodules - small abnormal masses in the lung - are detected incidentally on chest imaging in up to 50% of CT scans and are a key target of lung cancer screening programs. The vast majority are benign, but identifying the small fraction that are early lung cancers is critical for cure.
Australian and NZ Context The Thoracic Society of Australia and New Zealand (TSANZ) and the National Lung Cancer Screening Program (NLCSP) have developed this practical guide to standardize how clinicians manage screen-detected and incidentally detected pulmonary nodules (IPNs) across Australia and New Zealand.
Guide Scope The guide covers the full nodule management pathway: from initial detection and risk stratification, through imaging follow-up protocols and multidisciplinary team (MDT) review, to biopsy decision-making and emerging technologies including AI-based tools and novel biomarkers.
Target Audience The guide is designed for respiratory physicians, radiologists, thoracic surgeons, general practitioners, and radiographers who encounter pulmonary nodules in routine clinical practice. It provides actionable decision frameworks that balance the risk of missing lung cancer against the harms of unnecessary procedures.
PanCan Risk Model The Pan-Canadian Early Detection of Lung Cancer (PanCan) risk model uses nodule size, location, type (solid vs. subsolid), spiculation, and patient characteristics (age, smoking history, emphysema, family history) to estimate the probability that a pulmonary nodule is malignant. The model has been validated in multiple cohorts and forms the basis for management decisions.
Fleischner Society Guidelines The Fleischner Society guidelines provide size-based thresholds for follow-up imaging. Solid nodules smaller than 6 mm in low-risk individuals may require no follow-up, while larger or higher-risk nodules require serial CT imaging at defined intervals. The TSANZ guide adapts these thresholds to the Australian screening context.
Lung-RADS Classification Lung Imaging Reporting and Data System (Lung-RADS) provides a standardized reporting framework for CT-detected nodules, with categories from 1 (no nodule) to 4X (highly suspicious). Consistent use of Lung-RADS by radiologists reduces variability in reporting and enables clearer communication between radiologists and referring clinicians.
Subsolid Nodules Ground-glass nodules (GGNs) and part-solid nodules require different management algorithms than solid nodules. They are more likely to represent adenocarcinoma spectrum lesions (atypical adenomatous hyperplasia, adenocarcinoma in situ) and often require longer follow-up periods (up to 5 years) before discharge.
Lung Nodule Expert Team (LNET) The guide recommends establishment of dedicated Lung Nodule Expert Teams comprising respiratory physicians, thoracic radiologists, thoracic surgeons, and lung cancer nurse specialists. This team meets regularly to review higher-risk nodules and make collective management decisions.
MDM Workflow Pulmonary nodules meeting specified criteria (typically PanCan risk >10% or size thresholds) should be referred to an LNET multidisciplinary meeting (MDM). The MDM reviews imaging, clinical history, and risk factors, then recommends whether to continue surveillance imaging, proceed to biopsy, or consider surgical resection.
Nurse Specialist Role Lung cancer nurse specialists play a key role in coordinating nodule surveillance programs, ensuring patients attend follow-up appointments, communicating results, and providing emotional support. Patient anxiety about nodule surveillance is substantial, and dedicated nurse support significantly improves patient experience and follow-up completion rates.
Governance and Registry The guide recommends that nodule programs maintain patient registries to track nodule outcomes, monitor protocol adherence, and enable audit of program performance. Registry data is also essential for evaluating the effectiveness of risk models and identifying program improvement opportunities.
Biopsy Indications Not all pulmonary nodules require tissue diagnosis - many can be managed with imaging surveillance alone. Biopsy is indicated when the malignancy probability is intermediate (5-65%), the result will change management, and the procedural risk is acceptable. High-probability nodules in operable patients may proceed directly to surgical resection.
CT-Guided Transthoracic Needle Biopsy CT-guided biopsy is the most common tissue sampling approach for peripheral nodules and has a diagnostic yield of 85-95% for nodules larger than 2 cm. Complications include pneumothorax (20-25%), hemoptysis (5-10%), and rarely air embolism. Nodule size, depth, and emphysema presence are the main determinants of complication risk.
Bronchoscopic Approaches For more central or smaller nodules, bronchoscopic approaches including endobronchial ultrasound (EBUS), radial probe EBUS, and newer robotic bronchoscopy platforms (Monarch, Ion) provide tissue sampling with lower pneumothorax rates. Navigational bronchoscopy using CT-based 3D airway maps guides the bronchoscope to peripheral nodules.
Liquid Biopsy Circulating tumor DNA (ctDNA) and other blood-based biomarkers hold promise as non-invasive alternatives or adjuncts to tissue biopsy. While sensitivity for early-stage lung cancer remains limited, ctDNA analysis may help confirm malignancy or identify actionable mutations when tissue biopsy yields insufficient material.
AI Detection Performance AI-based computer-aided detection (CAD) systems for pulmonary nodules have reached sensitivities of 92-95% for nodules larger than 3 mm on CT, comparable to expert radiologist performance. These systems process CT volumes in seconds and flag candidate nodules for radiologist review, reducing the cognitive burden of screening reads.
Volume Measurement Accurate nodule volume measurement is critical for assessing growth over time. AI-based volumetry tools measure nodule volume with sub-voxel precision and calculate volume doubling time (VDT), which has become the preferred metric for assessing nodule growth. VDT below 400 days is concerning for malignancy.
Risk Stratification Assistance Some AI systems go beyond detection to perform malignancy risk stratification, generating probability scores based on nodule morphology, density distribution, and clinical features. These systems are being validated against the PanCan model and may eventually supplement clinical risk calculators.
Current Limitations Despite high sensitivity, AI systems have higher false-positive rates for subsolid nodules and can misclassify benign inflammatory lesions as suspicious. Lung-RADS classification accuracy, particularly for part-solid and ground-glass nodules, remains suboptimal for AI systems, requiring human radiologist oversight for final categorization.
Proteomics and Metabolomics Blood-based protein biomarkers such as the EarlyCDT-Lung test (measuring autoantibodies to 7 tumor-associated antigens) are being evaluated as adjuncts to CT screening. These tests could help triage nodule management, stratifying patients with intermediate-risk nodules toward more or less intensive follow-up.
Epigenetic Markers Methylation-based liquid biopsy tests that detect lung cancer-specific DNA methylation patterns in blood show early promise for improving the specificity of nodule risk assessment. These multi-cancer early detection (MCED) tests are entering large clinical validation trials.
Integration into Screening Programs Australia's NLCSP launched in 2023, providing high-risk individuals access to annual low-dose CT screening. As the program scales, standardized nodule management protocols, digital infrastructure for nodule registries, and quality benchmarks for LNET performance will be critical to program effectiveness and patient safety.
Research Priorities Key research priorities identified by TSANZ include: validation of AI tools in the Australian screening population, development of biomarkers that reduce benign biopsy rates, and evaluation of whether earlier MDT review improves outcomes for intermediate-risk nodules. Prospective data from the NLCSP will be invaluable for addressing these questions.